| scholarly article | Q13442814 |
| P2093 | author name string | Steven Grant | |
| Melissa Crawford | |||
| Kristy L. Richards | |||
| Lee M. Graves | |||
| Scott M. Hammond | |||
| Claudia M. Dollins | |||
| Eric I. Zimmerman | |||
| Serge P. Nana-Sinkam | |||
| P2860 | cites work | Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia | Q21144312 |
| Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis | Q24306444 | ||
| mir-29 regulates Mcl-1 protein expression and apoptosis | Q24652606 | ||
| Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing | Q24652787 | ||
| The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. | Q27824815 | ||
| FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). | Q27824823 | ||
| MicroRNAs modulate hematopoietic lineage differentiation | Q27860661 | ||
| microRNAs: tiny regulators with great potential | Q28214699 | ||
| A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia | Q28279141 | ||
| Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells | Q28287105 | ||
| miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts | Q30496174 | ||
| Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family | Q30971455 | ||
| The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. | Q33391782 | ||
| MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3 | Q33583422 | ||
| MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer | Q33668463 | ||
| Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase | Q33988398 | ||
| Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia | Q34048276 | ||
| Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia | Q34143211 | ||
| Individual microRNAs (miRNAs) display distinct mRNA targeting "rules" | Q34581040 | ||
| MicroRNA expression in cytogenetically normal acute myeloid leukemia | Q34775265 | ||
| Dynamic regulation of miRNA expression in ordered stages of cellular development. | Q35677284 | ||
| MicroRNAs as oncogenes | Q36345302 | ||
| Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia | Q37059746 | ||
| Unique biology of Mcl-1: therapeutic opportunities in cancer | Q37108463 | ||
| MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types | Q37641491 | ||
| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy | Q38361603 | ||
| MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. | Q39732104 | ||
| A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. | Q39895136 | ||
| Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. | Q40146009 | ||
| Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. | Q40182148 | ||
| A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. | Q40549569 | ||
| MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations | Q42554932 | ||
| BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. | Q44267685 | ||
| P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate | Q44729076 | ||
| Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells | Q47577367 | ||
| Src regulates the expression of Lin28: implications for cell growth, adhesion, and communication. | Q51733919 | ||
| Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. | Q54148912 | ||
| 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. | Q54224438 | ||
| p53/56(lyn) antisense shifts the 1,25-dihydroxyvitamin D3-induced G1/S block in HL60 cells to S phase | Q73594324 | ||
| Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c | Q73661196 | ||
| MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis | Q79849727 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| multiple drug resistance | Q643839 | ||
| drug resistance | Q12147416 | ||
| antineoplastic resistance | Q13416904 | ||
| P304 | page(s) | 811-817 | |
| P577 | publication date | 2010-08-06 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia | |
| Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia | |||
| P478 | volume | 78 |
| Q38587332 | Analogs, formulations and derivatives of imatinib: a patent review |
| Q28534259 | Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia |
| Q36375641 | BIRC6 mediates imatinib resistance independently of Mcl-1. |
| Q58780065 | Biological Aspects of mTOR in Leukemia |
| Q38500323 | Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes |
| Q37836936 | Chronic myeloid leukemia stem cells and developing therapies |
| Q47117016 | Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia |
| Q91987616 | Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells |
| Q97069617 | Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase |
| Q41890535 | Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia |
| Q27852520 | Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. |
| Q37968675 | Epigenetic regulation of osteoclast differentiation. |
| Q38833027 | Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells |
| Q37591850 | Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181. |
| Q34926222 | Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy |
| Q35832262 | MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2 |
| Q38815005 | MiR181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression |
| Q50904628 | MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. |
| Q37986129 | MicroRNA-181a - a tale of discrepancies |
| Q36057457 | MicroRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells |
| Q38667013 | MicroRNAs and Gastrointestinal Stromal Tumor |
| Q57170593 | MicroRNAs and immunity in periodontal health and disease |
| Q38599595 | MicroRNAs in Myeloid Hematological Malignancies. |
| Q38107272 | MicroRNAs in myeloid malignancies. |
| Q39392048 | MicroRNAs regulate B-cell receptor signaling-induced apoptosis |
| Q93018182 | Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs |
| Q38938169 | New insights into vitamin D anticancer properties: focus on miRNA modulation. |
| Q35137424 | Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest |
| Q47716556 | Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members |
| Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q36411230 | Specific Roles of MicroRNAs in Their Interactions with Environmental Factors |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q37729365 | The role of microRNAs in B-cell development and function |
| Q42117299 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine |
| Q35649100 | miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. |
| Q38862227 | miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model. |
| Q28087081 | miRNAs as Biomarkers in Chronic Myelogenous Leukemia |
| Q38979577 | miRNAs in chronic myeloid leukemia: small molecules, essential function |
| Q26778918 | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment |
| Q36905867 | microRNAs: innovative targets for cerebral ischemia and stroke. |
Search more.